Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5472858 | 0.76 | IGF1R (0.42) | EGLN1 | |
| SCHEMBL4890256 | 0.73 | NAMPT (0.40) | CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5190849 | 0.72 | IGF1R (0.41) | CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5484507 | 0.72 | FLT1 (0.36) | EGLN1 | |
| SCHEMBL4879679 | 0.71 | NR1H2 (0.36) | CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5478685 | 0.71 | KDM4E (0.32) | — | |
| SCHEMBL4882154 | 0.70 | IGF1R (0.32) | — | |
| SCHEMBL3727464 | 0.69 | IGF1R (0.41) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4884428 | 0.69 | IGF1R (0.33) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4883977 | 0.69 | NAMPT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | CDK1, PRKAR2B, MAP3K19 | EGLN1 2335/4885CYP1A2 803/4885CYP2C9 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.